FDA: No Medical Benefit From Marijuana
The Food and Drug Administration's statement contradicts a 1999 review by a panel of highly regarded scientists.
The Food and Drug Administration’s statement contradicts a 1999 review by a panel of highly regarded scientists.
Your support matters…N.Y. Times:
April 21, 2006 F.D.A. Dismisses Medical Benefit From Marijuana By GARDINER HARRIS
WASHINGTON, April 20 — The Food and Drug Administration said Thursday that “no sound scientific studies” supported the medical use of marijuana, contradicting a 1999 review by a panel of highly regarded scientists.
The announcement inserts the health agency into yet another fierce political fight.
Susan Bro, an agency spokeswoman, said Thursday’s statement resulted from a past combined review by federal drug enforcement, regulatory and research agencies that concluded “smoked marijuana has no currently accepted or proven medical use in the United States and is not an approved medical treatment.”
Ms. Bro said the agency issued the statement in response to numerous inquiries from Capitol Hill but would probably do nothing to enforce it.
Independent journalism is under threat and overshadowed by heavily funded mainstream media.
You can help level the playing field. Become a member.
Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.
Give today to support our courageous, independent journalists.
Editorial Cartoons
Women
A pharmacist and public health expert explain this new era in contraception.
Technology
Elon Musk's company has been hyping up human trials for years but only after a myriad of scandals around animal testing.
TD Original
In previously unreported statements made at the 2017 International Drug Policy Reform Conference, Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), discussed rumors of secret Pentagon studies with MDMA, as well as the reasons for hesitancy on the part of some government agencies to fund MAPS’ research.
The FDA’s strict guidance on test confirmations is one of several obstacles that has slowed the federal government’s response to COVID-19. The FDA could change its rules to speed things up, but hasn’t.
The agency's OK, four months after it rejected the drug over safety concerns, may stoke questions about standards for clearing medications.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.